UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 15, 2015
XBIOTECH INC.
(Exact name of registrant as specified in its charter)
British Columbia, Canada
(State of Incorporation)
001-37347
(Commission File Number)
N/A
(IRS Employer Identification No.)
| 8201 E Riverside Dr. Bldg 4, Ste 100 Austin, Texas |
78744 |
| (Address of principal executive offices) | (Zip Code) |
(512) 386-2900
(Registrant's telephone number, including area code)
________________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On July 15, 2015, XBiotech Inc. (the "Company"), announced that it will host its inaugural quarterly business update conference call and live webcast on July 28, 2015 at 8:30 a.m. Eastern Time to discuss results to date from its clinical trials and its R&D program.
The conference call can be accessed by dialing 866-295-6002 toll-free in the U.S. or 412-455-6209 for participants outside the U.S. (passcode: 86655088). The live audio webcast can be accessed on the Investor Relations section of the XBiotech website at www.investors.xbiotech.com. A replay of the call will be available on XBiotech's website for 90 days.
This Form 8-K and the related press release contains forward-looking statements, including declarations regarding management's beliefs and expectations, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosure set forth in "Risk Factors" in our SEC filings.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
99.1
Press Release of XBiotech Inc., issued July 15, 2015
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| XBIOTECH INC.
(Registrant) |
||
| July 16, 2015
(Date) |
/s/ JOHN SIMARD
John Simard Chief Executive Officer and President |
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
99.1 |
|
Press Release, issued July 15, 2015 |
EXHIBIT 99.1
XBiotech to Provide Second Quarter Business Update
AUSTIN, Texas, July 15, 2015 (GLOBE NEWSWIRE) -- XBiotech Inc., (NASDAQ:XBIT), the world's leading developer of next-generation True Human™ therapeutic antibodies, will host its inaugural quarterly business update conference call and live webcast on July 28, 2015, at 8:30am Eastern Time. The Company is hosting this quarterly update in the context of its achievement of very significant milestones both in the clinic and with its R&D programs.
John Simard, President and CEO of XBiotech, stated, "We are eager to provide an update where we can review the remarkable accomplishments we have made over our first quarter as a public company. There is nothing but good news to report and the Company's programs are firing on all cylinders. There is indeed tremendous excitement for our programs in cancer and infectious disease, as well as for our True Human antibody platform. With our strong cash position, excellent runway, advanced-stage assets and impressive commercialization infrastructure, the company represents a very compelling case. We look forward to the update call and invite all interested parties to mark the date."
For information on how to access the quarterly update call and live webcast, please visit the Events section of investors.xbiotech.com.
About XBiotech
XBiotech is pioneering a new era in the discovery and development of targeted antibodies based on its True HumanTM technology. The company's mission is to rethink the way antibody medicines are discovered and commercialized by advancing its robust pipeline of truly natural human antibodies for treating serious diseases such as cancer, inflammatory conditions and infectious diseases. XBiotech's lead product, Xilonix™, is a potential breakthrough antibody therapy that is currently the subject of two pivotal clinical studies for treating patients with advanced colorectal cancer. Xilonix specifically targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer. XBiotech's broad pipeline of True Human antibodies is able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. As such, True Human antibodies retain their natural physiology and tolerance profile, having passed the rigors of immune selection in the body. For more information, visit www.xbiotech.com.
CONTACT: Ashley Otero
XBiotech
aotero@xbiotech.com
512.386.2930
Tiberend Strategic Advisors, Inc.:
Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com
212.375.2664
Janine McCargo (media)
jmccargo@tiberend.com
646.604.5150